TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.

Inclusion Criteria: 1. Patients aged ≥18 years; 2. Patients with suspected cardiogenic cardiac arrest; 3. Patients with comatose state after ROSC (Glasgow Coma Scale \[GCS\] score \<9); 4. Patients with Return of spontaneous circulation (ROSC) sustained for \>20 minutes; Exclusion Criteria: 1. Cardiac arrest due to trauma; 2. Suspected or confirmed hemorrhagic or ischemic stroke; 3. Pregnancy; 4. Cardiac arrest without witnessed collapse; 5. Admission body temperature \<30°C; 6. Persistent cardiogenic shock (defined as systolic blood pressure below 90mmHg during the screening period despite adequate fluid resuscitation, vasopressors, and positive inotropic drug support); 7. Time from ROSC to randomization exceeding 4 hours; 8. Left ventricular ejection fraction (LVEF) \<35% after ROSC; 9. Known allergy to TNF - α antagonist components 10. Known tuberculosis or other active infection; 11. Diagnosed advanced malignant tumors with an estimated survival period of less than 6 months; 12. Pre-existing severe neurological dysfunction before cardiac arrest (e.g., Cerebral Performance Category \[CPC\] 3-4); 13. End stage renal disease relies on dialysis; 14. Severe chronic obstructive pulmonary disease (COPD) and other diseases require long-term home oxygen therapy; 15. Being in a state of severe immune suppression (such as long-term use of immunosuppressants after autoimmune diseases or organ transplantation, or patients with severe immunodeficiency diseases)； 16. History of liver cirrhosis; 17. History of chronic heart failure, heart function III-IV (NYHA)